These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29687559)

  • 21. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
    Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G
    Mult Scler; 2017 Nov; 23(13):1736-1747. PubMed ID: 28080250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
    Giovannoni G; Turner B; Gnanapavan S; Offiah C; Schmierer K; Marta M
    Mult Scler Relat Disord; 2015 Jul; 4(4):329-33. PubMed ID: 26195051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
    Prosperini L; Saccà F; Cordioli C; Cortese A; Buttari F; Pontecorvo S; Bianco A; Ruggieri S; Haggiag S; Brescia Morra V; Capra R; Centonze D; Di Battista G; Ferraro E; Francia A; Galgani S; Gasperini C; Millefiorini E; Mirabella M; Pozzilli C
    J Neurol; 2017 Feb; 264(2):284-294. PubMed ID: 27878443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.
    Smith AL; Cohen JA; Hua LH
    Neurotherapeutics; 2017 Oct; 14(4):952-960. PubMed ID: 28653282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term effects of corticosteroids in multiple sclerosis in terms of the "no evidence of disease activity" (NEDA) domains.
    Saied A; Elsaid N; Azab A
    Steroids; 2019 Sep; 149():108401. PubMed ID: 31100292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome Measures in Clinical Trials for Multiple Sclerosis.
    van Munster CE; Uitdehaag BM
    CNS Drugs; 2017 Mar; 31(3):217-236. PubMed ID: 28185158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.
    Stangel M; Penner IK; Kallmann BA; Lukas C; Kieseier BC
    Ther Adv Neurol Disord; 2015 Jan; 8(1):3-13. PubMed ID: 25584069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of methodological issues of clinical trials in multiple sclerosis.
    Montalban X
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S35-42. PubMed ID: 22206765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Bayesian hierarchical surrogate outcome model for multiple sclerosis.
    Pozzi L; Schmidli H; Ohlssen DI
    Pharm Stat; 2016 Jul; 15(4):341-8. PubMed ID: 27061897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing treatment success in multiple sclerosis.
    Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S
    J Neurol; 2016 Jun; 263(6):1053-65. PubMed ID: 26705122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
    J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M; Neuhaus A; Herbert J; Ebers G
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No evidence of disease activity (NEDA) in MS should include CSF biology - Towards a 'Disease-Free Status Score'.
    Bonnan M; Marasescu R; Demasles S; Krim E; Barroso B
    Mult Scler Relat Disord; 2017 Jan; 11():51-55. PubMed ID: 28104257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why some of us do not like the expression "no evidence of disease activity" (NEDA) in multiple sclerosis.
    Dadalti Fragoso Y
    Mult Scler Relat Disord; 2015 Jul; 4(4):383-4. PubMed ID: 26195061
    [No Abstract]   [Full Text] [Related]  

  • 38. Current therapeutic recommendations in multiple sclerosis.
    Berger T
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S37-45. PubMed ID: 20106347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain volume loss and no evidence of disease activity over 3 years in multiple sclerosis patients under interferon beta 1a subcutaneous treatment.
    Rojas JI; Sanchez F; Caro F; Miguez J; Patrucco L; Funes J; Cristiano E
    J Clin Neurosci; 2019 Jan; 59():175-178. PubMed ID: 30401571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.